Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
NEW YORK, Nov. 25, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc. (NASDAQ:LGND) securities between November 9, 2015 and November 14, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/ligand-pharmaceuticals. There is no cost or obligation to you.
According to the complaint, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ligand overstated the value of certain Deferred Tax Assets by approximately $27.5 million; (2) Ligand’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; (3) Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; (4) in turn, Ligand lacked effective internal control over financial reporting; and (5) as a result, Defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Ligand you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/ligand-pharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
